Europe Pharmacovigilance Market Size & Outlook, 2026-2033
Global Market
Related Markets
Europe pharmacovigilance market highlights
- The Europe pharmacovigilance market generated a revenue of USD 2,245.7 million in 2025.
- The market is expected to grow at a CAGR of 5.9% from 2026 to 2033.
- In terms of segment, phase iv was the largest revenue generating product life cycle in 2025.
- Phase III is the most lucrative product life cycle segment registering the fastest growth during the forecast period.
- Country-wise, Spain is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 2,245.7 million |
| Market revenue in 2033 | USD 3,620.3 million |
| Growth rate | 5.9% (CAGR from 2026 to 2033) |
| Largest segment | Phase iv |
| Fastest growing segment | Phase III |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre Clinical, Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | Accenture PLC Class A, IQVIA Holdings Inc, Cognizant Technology Solutions Corp Class A, Linical Americas, International Business Machines Corp, Labcorp Holdings Inc, ArisGlobal, Capgemini SE, ITClinical, Icon PLC, TAKE Solutions, PAREXEL, Wipro Ltd ADR, United Biosource Corporation, FMD K&L, BioClinica |
Other key industry trends
- In terms of revenue, Europe region accounted for 26.2% of the global pharmacovigilance market in 2025.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 4,742.2 million by 2033.
Europe is a favorable market for conducting phase I clinical trials due to the presence of a large foreign population, highly qualified staff, better quality of services & infrastructure, and ability to handle multiple-country clinical trials. According to WHO, 16,256 clinical trials were registered in 2020, the majority of which were by the European pharmaceutical industry.
This indicates the growth potential for PV services in this region. Rising demand for clinical trials and the need for novel drug development as a consequence of the rapidly growing geriatric population and increasing number of pharmaceutical and biotechnology firms are some of the high-impact rendering drivers of this market. Moreover, 3.5 million ADR reports were received by EudraVigilance in 2021, demonstrating a 93% increase in ADREs than the previous year.
Owing to the increase in mortality due to ADRs, the focus on adopting a proactive approach to ensure patient safety in Europe is growing. The European Medicine Agency (EMA) formulated the Risk Management Plan (RMP) for the governance of the PV system.
No credit card required*
Publish Date: Jun 05, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Pharmacovigilance Market Scope
Pharmacovigilance Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| International Business Machines Corp | View profile | 282,200 | One New Orchard Road, Armonk, NY, United States, 10504 | www.ibm.com |
| Wipro Ltd ADR | View profile | 244,707 | Sarjapur Road, Doddakannelli, Bangalore, KA, India, 560 035 | www.wipro.com |
| Accenture PLC Class A | View profile | 742,000 | 1 Grand Canal Square, Grand Canal Harbour, Dublin, Ireland, 2 | www.accenture.com |
| Cognizant Technology Solutions Corp Class A | View profile | 344,400 | 300 Frank West Burr Boulevard, Suite 36, 6th Floor, Teaneck, NJ, United States, 07666 | www.cognizant.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Icon PLC | View profile | 41,150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | www.iconplc.com |
| IQVIA Holdings Inc | View profile | 87,000 | 2400 Ellis Road, Durham, NC, United States, 27703 | www.iqvia.com |
| PAREXEL | View profile | 10001+ | Waltham, Massachusetts, United States, North America | www.parexel.com |
| ArisGlobal | View profile | 1001-5000 | Coral Gables, Florida, United States, North America | www.arisglobal.com |
| Capgemini SE | View profile | 340,400 | 11 rue de Tilsitt, Paris, France, 75017 | www.capgemini.com |
Europe Pharmacovigilance Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Pharmacovigilance Market Outlook will help companies and investors design strategic landscapes.
Phase Iv was the largest segment with a revenue share of 81.99% in 2025.
Horizon Databook has segmented the Europe pharmacovigilance market based on pre clinical, phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2021 to 2033.
Europe is a favorable market for conducting phase I clinical trials due to the presence of a large foreign population, highly qualified staff, better quality of services & infrastructure, and ability to handle multiple-country clinical trials. According to WHO, 16,256 clinical trials were registered in 2020, the majority of which were by the European pharmaceutical industry.
This indicates the growth potential for PV services in this region. Rising demand for clinical trials and the need for novel drug development as a consequence of the rapidly growing geriatric population and increasing number of pharmaceutical and biotechnology firms are some of the high-impact rendering drivers of this market. Moreover, 3.5 million ADR reports were received by EudraVigilance in 2021, demonstrating a 93% increase in ADREs than the previous year.
Owing to the increase in mortality due to ADRs, the focus on adopting a proactive approach to ensure patient safety in Europe is growing. The European Medicine Agency (EMA) formulated the Risk Management Plan (RMP) for the governance of the PV system.
- Europe Pharmacovigilance Market Product Life Cycle Outlook (Revenue, USD Million , 2021-2033)
- Pre Clinical
- Phase I
- Phase II
- Phase III
- Phase IV
- Europe Pharmacovigilance Market Service Provider Outlook (Revenue, USD Million , 2021-2033)
- In House
- Contract outsourcing
- Europe Pharmacovigilance Market Type Outlook (Revenue, USD Million , 2021-2033)
- Spontaneous reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
- Europe Pharmacovigilance Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceuticals
- Biotechnology Companies
- Medical Device Manufacturers
- Others
- Europe Pharmacovigilance Market Therapeutic Area Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Neurology
- Cardiology
- Respiratory Systems
- Others
- Europe Pharmacovigilance Market Process Flow Outlook (Revenue, USD Million , 2021-2033)
- Case Data Management
- Signal Detection
- Risk Management System
Reasons to subscribe to Pharmacovigilance Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Pharmacovigilance Market Outlook databook
- Our clientele includes a mix of Pharmacovigilance Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Pharmacovigilance Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Pharmacovigilance Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Pharmacovigilance Market, 2021-2033 (US$M)
Europe pharmacovigilance market statistics, by product life cycle, 2021-2033 (US$M)
